Patients in the US with the ultra-rare disease WHIM syndrome now have their first approved treatment, after X4 Pharma’s Xolremdi was given a green light by the FDA. Oral CXCR4 antagonist Xolremdi ...
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It ...
Firmware for the Xteink X4 e-paper display reader (unaffiliated with Xteink). Built using PlatformIO and targeting the ESP32-C3 microcontroller. CrossPoint Reader is a purpose-built firmware designed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback